If Biogen Idec (NASDAQ:BIIB) follows the usual pattern, the launch of BG-12 for multiple sclerosis isn't likely to generate huge investor enthusiasm (another example of "buy the rumor, sell the news"). That's particularly true given management's effort to take down the high end of BG-12 launch expectations within the last month. Accordingly, while Biogen Idec is a well-run franchise with a great niche in MS, and may well attract attention from a larger pharma, the company may need another exciting asset in its pipeline to keep up investor enthusiasm.
Good Execution In The Fourth Quarter...
Biogen Idec did well in terms of the reported numbers for the fourth quarter. Revenue rose 7% from last year and came in...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|